Results 311 to 320 of about 656,371 (370)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2021
PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) by next-generation sequencing (NGS) to inform the use and duration of ...
L. Costa +16 more
semanticscholar +1 more source
PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) by next-generation sequencing (NGS) to inform the use and duration of ...
L. Costa +16 more
semanticscholar +1 more source
Detection of minimal residual disease
2001Publisher Summary Minimal residual disease (MRD) is defined as the presence of a small number of cancer cells in hematological malignancies usually below 1010 cells (that amount approximately corresponds to 1g of the total cancer cell burden in a human body).
Sharon P. Mayer, A. Deptala
openaire +6 more sources
2012
Disease relapse remains a major problem in a significant proportion of patients treated for cancer. Molecular monitoring of minimal residual disease (MRD), usually using a real-time quantitative PCR-based approach, is an important tool for risk stratification and prognostication and can be used as a guide for optimizing clinical management in these ...
MUSSOLIN, LARA +2 more
openaire +4 more sources
Disease relapse remains a major problem in a significant proportion of patients treated for cancer. Molecular monitoring of minimal residual disease (MRD), usually using a real-time quantitative PCR-based approach, is an important tool for risk stratification and prognostication and can be used as a guide for optimizing clinical management in these ...
MUSSOLIN, LARA +2 more
openaire +4 more sources
Current Opinion in Hematology, 1995
The study of minimal residual disease has been fueled by the technologic advent of the polymerase chain reaction and basic developments identifying the genetic lesions involved in human malignancies. Thus far advances in identifying, cloning, and the subsequent polymerase chain reaction amplification of relevant genes have outpaced clinical studies ...
openaire +3 more sources
The study of minimal residual disease has been fueled by the technologic advent of the polymerase chain reaction and basic developments identifying the genetic lesions involved in human malignancies. Thus far advances in identifying, cloning, and the subsequent polymerase chain reaction amplification of relevant genes have outpaced clinical studies ...
openaire +3 more sources
Current Opinion in Hematology, 1999
Monitoring of residual disease in patients with malignant hematologic disorders has been recognized as an important diagnostic tool for assessment of the response to treatment and the individual risk of relapse. In a number of malignancies, employment of sensitive techniques permitting the identification of tumor cells within a 10(4)-fold or greater ...
openaire +3 more sources
Monitoring of residual disease in patients with malignant hematologic disorders has been recognized as an important diagnostic tool for assessment of the response to treatment and the individual risk of relapse. In a number of malignancies, employment of sensitive techniques permitting the identification of tumor cells within a 10(4)-fold or greater ...
openaire +3 more sources
Current Opinion in Hematology, 1998
A major limitation in the treatment of malignant disorders is the accurate and sensitive detection of minimal residual disease. It is clear that routine radiographic and pathologic studies are extremely important, however, lacking in sensitivity. Clearly, the goal of minimal residual disease detection is to make individual treatment decisions such that
openaire +3 more sources
A major limitation in the treatment of malignant disorders is the accurate and sensitive detection of minimal residual disease. It is clear that routine radiographic and pathologic studies are extremely important, however, lacking in sensitivity. Clearly, the goal of minimal residual disease detection is to make individual treatment decisions such that
openaire +3 more sources
Minimal residual disease in leukaemia patients
The Lancet Oncology, 2001Because of developments in diagnosis of haemopoietic malignant diseases during the past two decades, routine and reliable identification of very low numbers of malignant cells, known as minimal residual disease (MRD), is now possible. Several large-scale studies have shown that monitoring of MRD in haemopoietic malignant disease predicts clinical ...
Vincent Hj van der Valden +4 more
openaire +2 more sources
Minimal Residual Disease [PDF]
, 2009 During the past 30 years, survival rates after allogeneic stem cell transplantation (SCT) have been improved substantially. These improvements have mostly been due to better graft matching using genomic HLA typing, GVHD prophylaxis, infection management, and supportive care [1-3]. The incidence of leukemia relapse and death rates after relapse, however,
openaire +1 more source
Detection of Minimal Residual Disease
1995The ability to detect neoplastic infiltration is important not only for the accurate staging of disease at diagnosis but also to monitor the response to therapy. Although adult patients with advanced malignancies often achieve clinical complete remission, the majority of these patients ultimately relapse.
John G. Gribben, Lee M. Nadler
openaire +3 more sources
Detection of Minimal Residual Disease [PDF]
, 2020 Complete remission for hematolymphoid neoplasms affecting the bone marrow was traditionally considered to mean absence of morphologically detectable disease in the bone marrow with restoration of normal blood findings. Minimal residual disease (MRD) is the presence of the malignant cells at very low level (typically between 1% and 0.001% of total ...
openaire +1 more source